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Abstract
Background: The importance of 17b-estradiol (E2) in the prevention of large bowel tumorigenesis has been
shown in many epidemiological studies. Extragonadal E2 may form by the aromatase pathway from
androstenedione or the sulfatase pathway from estrone (E1) sulfate followed by E1 reduction to E2 by 17-b-
hydroxysteroid dehydrogenase (HSD17B1), so HSD17B1 gene expression may play an important role in the
production of E2 in peripheral tissue, including the colon.
Methods: HSD17B1 expression was analyzed in colorectal cancer cell lines (HT29, SW707) and primary colonic
adenocarcinoma tissues collected from fifty two patients who underwent radical colon surgical resection.
Histopathologically unchanged colonic mucosa located at least 10-20 cm away from the cancerous lesions was
obtained from the same patients. Expression level of HSD17B1 using quantitative PCR and western blot were
evaluated. DNA methylation level in the 5’ flanking region of HSD17B1 CpG rich region was assessed using bisulfite
DNA sequencing and HRM analysis. The influence of DNA methylation on HSD17B1 expression was further
evaluated by ChIP analysis in HT29 and SW707 cell lines. The conversion of estrone (E1) in to E2 was determined
by electrochemiluminescence method.
Results: We found a significant decrease in HSD17B1 transcript (p = 0.0016) and protein (p = 0.0028) levels in
colorectal cancer (CRC) from the proximal but not distal colon and rectum. This reduced HSD17B1 expression was
associated with significantly increased DNA methylation (p = 0.003) in the CpG rich region located in the 5’
flanking sequence of the HSD17B1 gene in CRC in the proximal but not distal colon and rectum. We also showed
that 5-dAzaC induced demethylation of the 5’ flanking region of HSD17B1, leading to increased occupation of the
promoter by Polymerase II, and increased transcript and protein levels in HT29 and SW707 CRC cells, which
contributed to the increase in E2 formation.
Conclusions: Our results showed that reduced HSD17B1 expression can be associated with DNA methylation in
the 5’ flanking region of HSD17B1 in CRC from the proximal colon.
Background
Colorectal cancer (CRC) is the third in the United States
[1] and second in Europe [2] cause of malignant disease
deaths among adults. Population based studies have
shown significant gender differences in CRC incidence
and mortality [3]. CRC occurrence is more frequent
among men than in pre-menopausal women, which sug-
gests a protective role of 17-b-estradiol (E2) in the
development of this cancer [3-5]. Moreover, many case-
control and cohort studies showed an inverse relation-
ship between the risk of CRC incidence and the use of
hormone replacement therapy by post-menopausal
women [6,7]. Although E2 is mainly biosynthesized by
the ovaries, this hormone can also be produced in
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can be formed by the aromatase pathway from the
androstenedione or the sulfatase pathway from estrone
(E1) sulfate, followed by E1 reduction to E2 by 17-b-
hydroxysteroid dehydrogenase (HSD17B1) [8,9]. There-
fore, HSD17B1 gene expression may play an important
role in the production of E2 in peripheral tissue.
HSD17B1 transcription may start from distal or proxi-
mal promoters, forming, respectively, the long (2.3-kb)
or short (1.3-kb) transcript, but the short mRNA is
thought to be translated into the HSD17B1 protein
(Additional file 1) [10-13].
Epigenetics involve variable usage of DNA due to
chromatin modifications without disturbances in the
DNA sequence [14]. The low level of DNA methylation
within 5’-CpG-3’ dinucleotides may relate to the activa-
tion of transcription or chromosomal instability [14,15].
It has been shown that, similarly to genetic mutations,
hypermethylation or hypomethylation of gene promoters
may change the expression of cancer related genes in
different malignancies, including CRC [14]. DNA methy-
lation is carried out by DNA methyltransferases
(DNMTs), and increased levels of some DNMTs
account for transcriptional silencing of cancer protective
genes [15].
We studied HSD17B1 transcript and protein levels in
primary cancerous tissue and histopathologically
unchanged colorectal tissue from the same fifty two
patients with CRC. We also evaluated the effect of 5-
Aza-2’-deoxycytidine (5-dAzaC), a DNMTs inhibitor, on
HSD17B1 transcript and protein levels in HT29 and
SW707 CRC cells. Moreover, we determined the level of
methylation in the 5’ flanking region of HSD17B1 in pri-
mary cancerous and histopathologically unchanged colo-
nic tissues as well as HT29 and SW707 CRC cells
treated with 5-dAzaC.
Methods
Patient material
Primary colonic adenocarcinoma tissues were collected
between June 2009 and June 2010 from fifty two
patients who underwent radical colon surgical resection
at the Department of General and Colorectal Surgery,
Poznań University of Medical Sciences, Poland (Table
1). Histopathologically unchanged colonic mucosa
located at least 10-20 cm away from the cancerous
lesions was obtained from the same patients. Samples
were immediately snap-frozen in liquid nitrogen and
stored at −80 º C until RNA/DNA/protein isolation. At
the time of surgery, the median and mean age of the
patients was 70 years (range 39-85) and 68.36 ± 11.7
years, respectively. Two of the patients exhibited T1
tumour stage, nine of the patients exhibited T2 tumour
stage, thirty seven patients exhibited T3 tumour stage
and four patients exhibited T4 tumour stage. Written
informed consent was obtained from all participating
individuals. The procedures of the study were approved
by the Local Ethical Committee of Poznań University of
Medical Sciences.
Antibodies and Reagents
Goat polyclonal (Gp) anti-HSD17B1 antibodies (Ab) (C-
18), donkey anti-goat horseradish peroxidase (HRP)-
conjugated Ab, anti-actin HRP-conjugated Ab (clone I-
19) and anti-Polymerase II (Pol II)-rabbit polyclonal Ab
( H - 2 2 4 )w e r ep r o v i d e db yS a n t aC r u zB i o t e c h n o l o g y
(Santa Cruz, CA). E1, 5-dAzaC was purchased from
Sigma-Aldrich Co. (St. Louis, MO). Goat anti-rabbit
HRP conjugated Ab was provided by DAKO (Glostrup,
Denmark).
Cell culture
HT29 colon cancer cells were obtained from the Ameri-
can Type Culture Collection (Rockville, MD) and
SW707 CRC cells were kindly provided by the Institute
of Immunology and Experimental Therapy of the Polish
Academy of Sciences. These cells were cultured in
DMEM GibcoBRL (Grand Island, NY) containing 10%
heat-inactivated fetal bovine serum (FBS) and 2 mM
glutamine. To determine the effect of 5-dAzaC on
HSD17B1 transcript and protein levels, the HT29 and
SW707 cells were cultured for 24 h in phenol red-free
DMEM GibcoBRL (Grand Island, NY) supplemented
with 10% charcoal-dextran-stripped FBS from Sigma-
Aldrich Co. (St. Louis, MO). Cells were then cultured
for 6, 12, 24, 36 and 48 h either in the absence or in the
presence of 5-dAzaC at concentrations of 0.33, 0.66 and
1.00 μM. These cells were used for total RNA isolation,
western blotting, chromatin immunoprecipitation (ChIP)
assay, and bisulfite sequencing.
Reverse transcription and real-time quantitative
polymerase chain reaction (RQ-PCR) analysis of the
HSD17B1 transcript levels
The total RNA from primary tissues of patients with
CRC and from HT29 and SW707 cells was isolated
according to the method of Chomczyński and Sacchi
(1987) [16]. RNA samples were treated with DNase I,
quantified, and reverse-transcribed into cDNA. RQ-PCR
was carried out in a Light Cycler real-time PCR detec-
tion system from Roche Diagnostics GmbH, (Man-
nheim, Germany) using SYBR
® Green I as detection
dye. The target cDNA was quantified by relative quanti-
fication method using a calibrator for primary tissue or
respective controls for HT29 and SW707 cells. The cali-
brator was prepared as a cDNA mix from all of the
patients’ samples and successive dilutions were used to
create a standard curve as described in Relative
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nheim, Germany). For amplification, 1 μl of cDNA solu-
tion was added to 9 μlo fI Q ™ SYBR
® Green Supermix
Bio-Rad Laboratories Inc. (Hercules, CA) and primers
(Additional file 1, Additional file 2). The quantity of
transcript of HSD17B1 in each sample was standardized
by the geometric mean of porphobilinogen deaminase
(PBGD) and human mitochondrial ribosomal protein
L19 (hMRPL19) cDNA levels (Additional file 2) [17,18].
The transcript levels in patient tissues were expressed as
multiplicity of these cDNA concentrations in the cali-
brator. In HT29 and SW707 cells, transcript levels were
presented as multiplicity of the respective controls.
Western blotting analysis
Primary tissue from patients with CRC and HT29 and
SW707 cells were treated with lysis RIPA buffer, and 40 μg
of protein were resuspended in sample buffer and sepa-
rated on 12% Tris-glycine gel using sodium dodecyl sul-
fate-polyacrylamide gel electrophoresis (SDS-PAGE). Gel
proteins were transferred to a polyvinylidene fluoride
(PVDF) membrane, which was blocked with 5% milk in
Tris/HCl saline/Tween buffer. Immunodetection of bands
was performed with Gp anti-HSD17B1 Ab (C-18), followed
by incubation with donkey anti-goat HRP-conjugated Ab.
To ensure equal protein loading of the lanes, the mem-
brane was re-stripped and incubated with anti-actin HRP-
conjugated Ab (clone I-19). Bands were revealed using
ECL kit and Hyperfilm ECL Amersham (Piscataway, NJ).
The amounts of HSD17B1 protein was presented as the
HSD17B1 to-b-actin band optical density ratio. For HT29
and SW707 cells cultured in the absence of 5-dAzaC, the
ratio of HSD17B1 to b-actin was assumed to be 1.
DNA methylation evaluation by bisulfite sequencing
Genomic DNA was isolated using DNA Mammalian
Genomic Purification Kit purchased from Sigma-Aldrich
C o .( S t .L o u i s ,M O ) .O n eμg of genomic DNA was sub-
jected to bisulfite conversion of cytosine to uracil
according to EZ DNA Methylation Kit™ procedure
Table 1 HSD17B1 transcript and protein levels in primary cancerous and histopathologically unchanged tissue
samples from patient with CRC.
n = 52 Primary cancerous tissues Histopathologically unchanged tissues P
c
Median (range) Mean (± SD) Median (range) Mean (± SD)
Age (Years)
<60 10 3.511 (2.109-3.868)
a 3.282 ± 0.5921
a 3.415 (2.726-5.107)
a 3.611 ± 0.6309
a 0.2450
a
2.634 (1.681-3.218)
b 2.579 ± 0.5243
b 2.620 (2.108-3.398)
b 2.719 ± 0.4843
b 0.5423
b
>60 42 3.531 (2.071-5.227)
a 3.569 ± 0.6649
a 3.692 (2.790-5.785)
a 3.834 ± 0.6251
a 0.1087
a
2.728 (1.728-4.023)
b 2.720 ± 0.4702
b 2.952 (1.364-3.472)
b 2.835 ± 0.4913
b 0.1121
b
Gender
Female 20 3.384 (2.109-4.455)
a 3.371 ± 0.5676
a 3.449 (2.726-5.785)
a 3.719 ± 0.7333
a 0.2340
a
2.793 (1.681-3.218)
b 2.666 ± 0.4767
b 2.811 (2.108-3.472)
b 2.844 ± 0.4065
b 0.2119
b
Male 32 3.571 (2.071-4.653)
a 3.557 ± 0.6523
a 3.857(2.790-5.259)
a 3.890 ± 0.5855
a 0.0388
a
2.702 (1.728-4.023)
b 2.713 ± 0.4941
b 2.962 (1.364-3.449)
b 2.792 ± 0.5395
b 0.2832
b
CRC localization
Proximal colon (cecum to transverse) 20 3.507(2.666-4.455)
a 3.427 ± 0.4350
a 3.874 (3.050-5.785)
a 4.057 ± 0.7488
a 0.0016
a
2.793 (1.681-3.218)
b 2.666 ± 0.4767
b 2.811 (2.108-3.472)
b 2.844 ± 0.4065
b 0.0028
b
Distal colon (splenic flexture to sigmoid) 12 3.214 (2.071-4.313)
a 3.218 ± 0.7760
a 3.449 (2.726-4.587)
a 3.630 ± 0.6372
a 0.1685
a
2.798 (1.772-3.254)
b 2.691 ± 0.4777
b 2.860 (1.364-3.391)
b 2.619 ± 0.6350
b 0.7763
b
Rectum 20 3.544 (2.523-4.653)
a 3.657 ± 0.6011
a 3.564 (3.226-4.862)
a 3.762 ± 0.500
a 0.8839
a
2.951 (1.728-3.398)
b 2.815 ± 0.4436
b 2.988 (2.019-3.383)
b 2.913 ± 0.3871
b 0.5019
b
Histologic grade
G1 4 4.059 (2.362-4.402)
a 3.721 ± 0.9467
a 4.431 (3.123-5.259)
a 4.311 ± 0.9076
a 0.4026
a
2.926 (2.586-3.040)
b 2.870 ± 0.2060
b 2.789 (2.026-3.147)
b 2.688 ± 0.5370
b 0.5506
b
G2 35 3.379 (2.109-4.621)
a 3.363 ± 0.5385
a 3.524 (2.726-5.785)
a 3.681 ± 0.5619
a 0.0335
a
2.647 (1.681-4.023)
b 2.649 ± 0.4993
b 2.933 (2.019-3.472)
b 2.863 ± 0.4114
b 0.0659
b
G3 13 3.875 (2.071-4.839)
a 3.807 ± 0.7092
a 4.043 (2.790-5.227)
a 4.165 ± 0.7346
a 0.2587
a
2.676 (1.845-3.431)
b 2.670 ± 0.5098
b 3.023 (1.364-3.449)
b 2.763 ± 0.6858
b 0.5114
b
The HSD17B1 transcript levels
a were standardized by the geometric mean of PBGD and hMRPL19 cDNA and expressed as decimal logarithm of multiples of these
cDNA copies in calibrator.
b The amount of western blot-detected proteins was presented as the decimal logarithm HSD17B1 to b-actin band optical density
ratio.
c Unpaired, two-tailed t-test or U-Mann-Whitney test.
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Page 3 of 13from Zymo Research Corporation (Orange, CA). The
position of CpG islands (chr17: 37 953 426 - 37 954
646) and binding sites of transcription factors located in
the 5’ flanking region of the promoter was determined
by online programs [19-21] (Additional file 1). A DNA
fragment containing 31 CpG dinucleotides was amplified
from the bisulfite-modified DNA by the primer pair
(chr17: 37 953 392-37 953 917) (Additional file 1, Addi-
tional file 2) complementary to the bisulfite-DNA modi-
fied sequence. PCR amplification was performed by
FastStart Taq DNA Polymerase from Roche Diagnostic
GmbH (Penzberg, Germany). The PCR products were
purified using Agarose Gel DNA Extraction Kit Roche
(Mannheim, Germany) with subsequent cloning into
pGEM-T Easy Vector System I Promega (Madison, WI)
and transformation into TOPO10 E. coli strain cells.
Plasmid DNA isolated from ten positive bacterial clones
was used for commercial sequencing of the cloned frag-
ment of DNA. The results of bisulfite sequencing were
assessed and presented using BiQ analyzer software and
the Bisulfite sequencing Data Presentation and Compila-
tion (BDPC) web server, respectively [22,23].
DNA methylation assessment by high resolution melting
(HRM) analysis
Methylation levels of three DNA fragments located
within the CpG rich region (Additional file 1) were
determined by Real Time PCR amplification of bisulfite
treated DNA, followed by HRM profile analysis by
CFX96™ Real-Time PCR Detection System, Bio-Rad
Laboratories Inc. (Hercules, CA). For PCR amplification,
1 μl solution of bisulfite treated DNA, from patients or
standards, and primers (Additional file 1, Additional file
2) was added to 19 μl of 5 × Hot FIREPol EvaGreen
HRM Mix, Solis BioDyne Co. (Tartu, Estonia). Stan-
dards of DNA methylation percentage were prepared by
mixing in different ratio methylated and non-methylated
bisulfite treated DNA from Human Methylated/Non-
methylated DNA Set Zymo Research Corp. (Orange,
CA). To determine the percentage of methylation, the
HRM profiles of patient DNA PCR products were com-
pared with HRM profiles of standard DNA PCR product
[24] (Additional file 3). HRM methylation analysis was
performed using Precision Melt Analysis™ Software,
Bio-Rad Laboratories Inc. (Hercules, CA). Each PCR
amplification and HRM profile analysis was performed
in triplicate. The methylation for each patient was pre-
sented as a percentage of methylation in three amplified
fragments located in the CpG rich region of HSD17B1.
ChIP analysis
HT29 and SW707 cells were maintained in phenol red-
free DMEM GibcoBRL supplemented with 10% char-
coal-dextran-stripped FBS for 6, 12, 24, 36 and 48 h
either in the absence or in the presence of 5-dAzaC at a
concentration of 1.00 μM. Cells were then fixed by the
addition of 270 μL of 37% formaldehyde to 10 mL of
culture medium for 10 min at 37 ºC, and harvested.
Chromatin from 10
6 cells was sheared by sonicator and
precleared with salmon sperm DNA-saturated protein G
sepharose. The ChIP assay was conducted using Abcam
ChIP Kit ab500 [25]. Chromatin was incubated with 2
μg of rabbit polyclonal anti-Pol II Ab (H-224) overnight
at 4 ºC. The input and immunoprecipitated DNA were
used as templates for Real Time PCR preformed using
the primers corresponding to the promoter of the
HSD17B1 gene (Additional file 1, Additional file 2). The
percentage of HSD17B1 promoter that was bound with
Pol II was calculated based on the differences between
CT values for input and DNA samples from cells treated
or untreated with 5-dAzaC.
Effect of 5-dAzaC on the conversion of E1 to E2 in HT29
and SW707 cells
To determine the effect of 5-dAzaC on the conversion
of E1 to E2, the HT29 and SW707 cells were main-
tained for 24 h in phenol red-free DMEM GibcoBRL
supplemented with 10% charcoal-dextran-stripped FBS
from Sigma-Aldrich Co. Cells were then cultured for 36
h either in the absence or in the presence of 5-dAzaC at
a concentration of 1.00 μM for HT29 and SW707 cells.
These cells were then further cultured either in the
absence or the presence of E1 at a concentration of 10
−2
mM. After 2, 4, 6, 8, 10 and 12 h, 0.5 ml of the medium
was collected and the concentration of E2 was deter-
mined by electrochemiluminescence method using
Cobas 6000 Roche Diagnostics GmbH (Mannheim, Ger-
many). The results were expressed as E2 concentration
in culture medium in nM per μg cell protein.
Statistical analysis
Data groups for cell lines were assessed by ANOVA to
evaluate if there was significance (P <0 . 0 5 )b e t w e e nt h e
groups. For all experimental groups, which fulfilled the
initial criterion, individual comparisons were performed
by post hoc Tukey test with the assumption of two-tailed
distribution and two samples with equal variance at the
P < 0.05 level. Statistical significance was designated by
asterisks in the figures.
The normality of the observed patient data distribu-
tion was assessed by Shapiro-Wilk test, and parametric
unpaired, two-tailed t-test or nonparametric U-Mann-
Whitney test was used to compare the mean values. P <
0.05 was considered statistically significant. The correla-
tion between mRNA and protein levels was evaluated by
Spearman nonparametric correlation coefficient method.
The statistical analysis was performed with STATIS-
TICA 6.0 software.
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HSD17B1 transcript and protein levels in primary
cancerous and histopathologically unchanged tissues
from patients with CRC
To compare HSD17B1 transcript and protein levels in
cancerous and histopathologically unchanged tissues
from patients with CRC we used RQ-PCR and western
blotting analysis, respectively. We found significantly
lower levels of HSD17B1 transcript (p = 0.0016) and
protein (p = 0.0028) in primary cancerous tissues than
in histopathologically unchanged tissues in patients with
CRC in the proximal colon (Figure 1A,B,C and Table 1).
Moreover, we observed a moderate correlation between
mRNA and protein in cancerous (p = 0.0502) and histo-
pathologically unchanged tissue (p = 0.0722) in the
proximal colon. We also observed significantly lower
amounts of HSD17B1 transcript (p = 0.0335, p =
0.0388) and protein (p = 0.0659, p = 0.2832) in cancer-
ous tissues compared to histopathologically unchanged
tissues in patients with G2 histological grade and male
patient group, respectively. There were no significant
differences in transcript (p = 0.1685, p = 0.8839) and
HSD17B1 protein (p = 0.7763, p = 0.5019) levels
between primary cancerous and histopathologically
unchanged tissues in patients with CRC located in the
distal colon and rectum (Table 1). We also did not
observe differences in HSD17B1 transcript and protein
levels between these tissues in the female patient group,
different ages, G1/G3 histological grade (Table 1), and
different tumour stage (not shown).
DNA methylation levels in primary cancerous and
histopathologically unchanged tissues from patients with
CRC
To compare DNA methylation levels in the HSD17B1
CpG rich region between DNA from cancerous and his-
topathologically unchanged tissues, we performed
sodium bisulfite DNA sequencing and HRM analysis
(Additional file 1, Additional file 2). Bisulfite sequencing
was used for preliminary evaluation of DNA methylation
changes in randomly selected patients. We observed the
same pattern of methylation within all individual clones
of each patient. Moreover, this evaluation showed signif-
icant differences in DNA methylation levels between
cancerous and histopathologically unchanged tissues
from five patients with CRC in the proximal colon (Fig-
ure 2A). However, we did not observe this difference in
five patients with CRC located in the distal colon (Fig-
ure 2B) or rectum (not shown). We applied HRM analy-
sis of PCR amplified bisulfite treated DNA to extend the
DNA methylation studies in the HSD17B1 CpG rich
region for cancerous and histopathologically unchanged
tissues from all fifty two patients. In patients with CRC
located in the proximal colon, we found a significantly
higher DNA methylation percentage in cancerous than
in histopathologically unchanged tissues (p = 0.003)
(Table 2). However, there were no significant differences
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Figure 1 HSD17B1 transcript (A) and protein (B) levels and
representative picture of western blot (C) in primary cancerous
and histopathologically unchanged tissues from patients with
CRC in the proximal colon. The cancerous (●)a n d
histopathologically unchanged tissues (○) from twenty patients with
CRC in the proximal colon were used for RNA and protein isolation.
Total RNA was reverse-transcribed, and cDNAs were investigated by
RQ-PCR relative quantification analysis. The HSD17B1 mRNA levels
were corrected by the geometric mean of PBGD and hMRPL19 cDNA
levels. The amounts of HSD17B1 mRNA were expressed as the decimal
logarithm of multiples of these cDNA copies in the calibrator. Proteins
were separated by 12% SDS-PAGE, and transferred to a membrane
that was then immunoblotted with Gp anti- HSD17B1 Ab and
incubated with donkey anti-goat HRP-conjugated Ab. The membrane
was then reblotted with anti-actin HRP-conjugated Ab. The amount of
western blot-detected HSD17B1 proteins was presented as the
decimal logarithm of HSD17B1 to b-actin band optical density ratio.
The p value was evaluated by unpaired, two-tailed t-test.
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Figure 2 Bisulfite sequencing of DNA CpG rich region in primary tissue samples from patients with CRC in the proximal (A) and distal
(B) colon. The primary cancerous and histopathologically unchanged tissues from the same patients with cancer in the proximal (P1-P5) and
distal colon (P6-P10) were used for genomic DNA isolation followed by bisulfite conversion of cytosine to uracil. The HSD17B1 region containing
31 CpG dinucleotides (chr17: 37 953 392-37 953 917) was then amplified by a pair of primers complementary to the bisulfite-DNA modified
sequence (Additional file 1, Additional file 2). The PCR products were purified with subsequent cloning into a plasmid vector. Plasmid DNA
isolated from ten positive bacterial clones was used for commercial sequencing. The results of bisulfite sequencing were assessed and presented
using BiQ analyzer software and BDPC web server, respectively [22,23]. Black and grey boxes represent methylated and unmethylated CpG
dinucleotide, respectively. White boxes correspond to undetermined CpG dinucleotide. The legend with grey scale corresponds to average
methylation in (P1-P5) and (P6-P10).
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Page 6 of 13in DNA methylation percentage between cancerous and
histopathologically unchanged tissues from patients with
CRC located in the distal colon (p = 0.7498) and rectum
(p = 0.9810) (Table 2). We also did not find significant
differences in the DNA methylation percentage between
these tissues in patients divided based on gender, age,
histological grade (Table 2) and tumour stage (not
shown).
5-dAzaC effects on HSD17B1 transcript and protein
contents in HT29 and SW707 colorectal cancer cells
We observed that 5-dAzaC resulted in a progressive
increase in HSD17B1transcript levels in HT29 and
SW707 cells (Figure 3A,B). For HT29 cells, we found
approximately a 1.91- fold significant increase in
HSD17B1 transcript levels at 48 h of incubation (Figure
3A). There was also an approximately 1.35-fold signifi-
cant increase in HSD17B1 mRNA in SW707 cells at 48 h
of incubation (Figure 3B). These alterations in HSD17B1
transcript levels in both HT29 and SW707 cells were
associated with increased HSD17B1 protein levels (Figure
4). Densitometric analysis of western blotting bands indi-
cated a gradual increase of HSD17B1 protein levels in a
dose dependent manner at 24, 36, and 48 h of incubation
for HT29 cells, and at 48 h for SW707 cells (Figure 4).
Incubation of HT29 cells with 5-dAzaC at a concentra-
tion of 1.00 μM for 48 h resulted in a 2.28-fold increase
in HSD17B1 protein contents (Figure 4). There was also
an approximately 1.57-fold increase in HSD17B1 protein
contents in SW707 cells incubated with 5-dAzaC at a
concentration of 1.00 μM for 48 h as compared with the
respective control (Figure 4).
5-dAzaC induced transcription of HSD17B1 via DNA
demethylation in the CpG rich region and increased the
binding of Pol II to the promoter in HT29 colon cancer cells
In order to assess the effect of 5-dAzaC on DNA
demethylation and Pol II binding to the promoter we
used bisulfite DNA sequencing and the ChIP assay,
respectively (Additional file 1). We noticed the same
pattern of methylation within all analysed clones. More-
over, we observed significant DNA demethylation in the
CpG rich region in HT29 cells cultured for 48 h in the
presence of 5-dAzaC (Figure 5A). Incubation with 5-
dAzaC at a concentration of 1.00 μM for 6, 12, 24, 36,
and 48 h caused an approximately 1.56 to 6.70-fold
increase in the percentage of promoter occupancy by
Pol II in HT29 colon cancer cells (Figure 5B). However,
in SW707 CRC cells treated with 5-dAzaC at a concen-
tration of 1.00 μM, we observed slight DNA demethyla-
tion and slight increased occupancy percentage of the
promoter by Pol II (Figure 5A,B).
5-dAzaC increased the conversion of E1 to E2 in HT29
and SW707 colorectal cancer cells
5-dAzaC caused a progressive increase in the conversion
of E1 to E2 in a time dependent manner in 5-dAzaC
pretreated HT29 cells at 6, 8, 10 and 12 h of incubation
(Figure 6A). Incubation of 5-dAzaC pretreated HT29
cells with E1 for 12 h resulted in a 3.0-fold increase in
Table 2 The percentage of DNA methylation in CpG rich regions in primary cancerous and histopathologically
unchanged tissue samples from patients with CRC.
n = 52 Primary cancerous tissues Histopathologically unchanged tissues p
a
Median (range) Mean (± SD) Median (range) Mean (± SD)
Age
<60 10 21.05 (12.89-25.79) 20.66 ± 4.205 19.47 (13.16-28.42) 19.32 ± 4.875 0.5181
>60 42 20.00 (4.211-33.16) 20.91 ± 7.074 18.95 (2.105-36.21) 18.42 ± 6.779 0.1076
Gender
Female 20 24.21 (16.84-33.16) 24.42 ± 4.516 23.68 (13.68-28.42) 21.75 ± 4.499 0.1155
Male 32 18.95 (4.211-32.11) 19.51 ± 7.255 17.37 (2.105-36.21) 18.43 ± 7.206 0.5594
CRC localization
Proximal colon (cecum to transverse) 20 24.21 ( 13.68-33.16) 23.54 ± 5.793 17.63 ( 2.105435.79) 17.61 ± 6.050 0.0030
Distal colon (splenic flexture to sigmoid) 12 19.47 (4.211-28.95) 19.69 ± 7.159 18.95 (10.53-25.26) 18.85 ± 4.747 0.7498
Rectum 20 19.47 (6.316-28.42) 19.36 ± 6.292 19.47 (4.737-36.21) 19.30 ± 7.851 0.9810
Histologic grade
G1 4 21.32 (13.68-28.42) 21.18 ± 8.067 17.89 (2.105-27.89) 16.45 ± 10.97 0.5126
G2 35 20.00 (10.53-30.53) 21.17 ± 5.293 19.47 (4.737-28.42) 18.93 ± 5.884 0.0996
G3 13 21.84 (4.211-33.16) 20.21 ± 9.397 15.53 (12.63-36.21) 18.11 ± 6.727 0.4021
The primary cancerous and histopathologically unchanged tissue samples from the same patients were used for genomic DNA isolation, followed by bisulfite
conversion of cytosine to uracil. The three DNA fragments of the CpG rich region were then amplified by three pairs of primers complementary to the bisulfite-
DNA modified sequence (Additional file 1, Additional file 2). To determine the percentage of methylation, the HRM profiles of the patients’ DNA PCR products
were compared to HRM profiles of the prepared standard PCR products. DNA methylation for each patient was presented as a percentage of methylation in
three DNA amplified fragments located in the CpG rich region (Additional file 1).
a Unpaired, two-tailed t-test.
Rawłuszko et al. BMC Cancer 2011, 11:522
http://www.biomedcentral.com/1471-2407/11/522
Page 7 of 13E2 levels as compared to 5-dAzaC untreated cells (Fig-
ure 6A). There was also a slight, 1.2-fold, increase in E2
concentration in 5-dAzaC pretreated SW707 cells at 12
h of incubation as compared with the respective control
(Figure 6B).
Discussion
There are many environmental, dietary, lifestyle, beha-
vioral, genetic and epigenetic factors that have been
considered as risk factors for developing CRC [26-30].
Malignant transformation of colonic mucosa to ade-
noma and adenocarcinoma is associated with the accu-
mulation of mutations in various oncogenes, tumour
suppressor genes (TSGs) and chromosome, and micro-
satellite instability [29,31]. Alternatively, the epigenetic
mechanism has also been considered as a strong contri-
butor to CRC incidence. Aberrant methylation of DNA
may mimic DNA mutation, leading to transcriptional
silencing of TSGs and chromosome instability [15].
Accessibility of E2 is another significant factor contri-
buting to the development of CRC. The randomized
clinical trial conducted by the Women’s Health Institute
showed that treatment of postmenopausal women with
E2 plus progestin was associated with a decreased risk
of CRC [32]. In contrast, treatment of these women
with E2 alone exhibited a rather slight increased risk of
CRC [32]. However, the importance of E2 in the preven-
tion of large bowel tumorigenesis has been shown in
other epidemiological studies [3,5,33]. E2 exerts an
apoptotic effect in CRC cells mainly via interaction with
the estrogen receptor (ER) [34-36]. This apoptotic effect
of E2 in CRC can be inhibited by DNA methylation and
silencing of transcription of the ESR2 gene encoding
ERb [35,37]. Papaxoinis et al. [38] showed that ESR2
expression is higher in normal epithelium of the proxi-
mal colon as compared to the distal colon. This indi-
cated that epigenetic silencing of ESR2 appearing in 90%
of CRC cases could mainly be associated with carcino-
genesis in the proximal colon [39]. Moreover, the cohort
studies indicated that, in postmenopausal women, CRC
more frequently developed in the proximal colon than
in the distal colon [40,41]. These findings may indicate
that the proximal colon may be the major bowel region,
compared to the distal colon, in which E2 may mainly
exert its anticancer action [42]. Fiorelli et al. (2002)
showed the involvement of HSD17B1 in the conversion
of E1 to E2 in human colon cancer cells [43]. This may
suggest that the extragonadal production of E2 from E1,
especially in the large bowel, may be critical in CRC
incidence in postmenopausal women and in men.
During CRC development, epithelial cells acquire
peculiar features which enable them to grow aberrantly,
ignore growth inhibition, and resist death signals [44].
We found a significant reduction of HSD17B1 transcript
and protein levels in CRC in the proximal colon. How-
ever, these differences were not found in CRC in the
distal colon and rectum. The decreased expression of
HSD17B1 was associated with significantly increased
DNA methylation in the CpG rich region located in the
5’ flanking region of the HSD17B1 gene in CRC in the
proximal colon but not in the distal colon and rectum.
Abnormalities in DNA methylation are observed from
the early stages of lesions in aberrant crypt foci and
hyperplastic polyps considered to be CRC incidence risk
factors [45,46]. To date, transcriptional silencing by
DNA methylation has been demonstrated in hMLH1,
PDZ and LIM domain 2, UDP-glucuronosyltransferase
1A1, HOXB13, CXCL12 and other genes in CRC
[31,47-50]. Moreover, there is a distinction between
tumorigenesis associated with DNA methylation and
gene expression when comparing the proximal colon to
the distal colon and rectum [30,51]. Carcinogenesis in
the proximal colon is mainly associated with epigenetic
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Figure 3 5-dAzaC up-regulates HSD17B1 transcript levels in HT29
(A) and SW707 (B) colorectal cancer cells.H T 2 9a n dS W 7 0 7c e l l s
were cultured in phenol red-free DMEM for 6, 12, 24, 36 and 48 h either
in the absence or in the presence of 5-dAzaC at a concentration of 1.00
μM. After incubation the cells were used for total RNA isolation and
reverse transcription. The HSD17B1 cDNA levels were determined by
RQ-PCR relative quantification analysis. RQ-PCR results were
standardized by the geometric mean of PBGD and hMRPL19 cDNA
levels. HSD17B1 cDNA levels are expressed as a multiplicity of the
respective controls. Each sample was determined in triplicate and results
are presented as the mean ± SE from three experiments *P < 0.05.
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Page 8 of 13aberrations, whereas cancer incidence in the distal colon
and rectum is mainly linked to the accumulation of
genetic mutations [51]. Glebov et al. (2003) used micro-
array analysis to demonstrate that more than 1000
genes are expressed differently in CRC depending on its
location in either the ascending or descending colon
[52]. Toyota et al. (1999) characterized the CpG island
methylator phenotype (CIMP) in CRC [53]. CRC with
CIMP-high develops more frequently in the proximal
colon, while CIMP-low or CIMP-negative is likely to be
found in the distal colon [30,51]. Hypermethylation of
the promoter region of hMLH1, encoding a component
of the DNA mismatch repair system, was also more fre-
quently found in CRC in the proximal colon than in the
distal colon [31].
In order to determine the role of methylation of the
CpG rich region in HSD17B1 expression, we treated
HT29 and SW707 cells with 5-dAzaC. We observed
DNA demethylation within the CpG rich region
(chr17: 37 953 426-37 954 646) (Additional file 1),
which was associated with an increase in Pol II binding
to the promoter and increased the HSD17B1 transcript
Figure 4 5-dAzaC effect on HSD17B1 protein levels in HT29 and SW707 colorectal cancer cells. Cells were cultured in phenol red free
DMEM media for 6, 12, 24, 36 and 48 h either in the absence or in the presence of 5-dAzaC at a concentration of 0.33, 0.66 and 1.00 μM. The
cell protein was separated by 12% SDS-PAGE, and transferred to a membrane that was then immunoblotted with Gp anti-HSD17B1 Ab and
incubated with donkey anti-goat HRP-conjugated Ab. The membrane was then reblotted with anti b-actin HRP-conjugated Ab. The band
densitometry readings were normalized to b-actin loading control. The ratio HSD17B1 to b-actin for control was assumed to be 1.
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Page 9 of 13and protein levels in HT29 cells. However, 5-dAzaC
treatment caused lower DNA demethylation and bind-
ing of Pol II to promoter in SW707 cells than in HT29
cells. These differences between HT29 and SW707
cells might be due to their distinct regions of origin
from the large bowel: SW707 cells were derived from
the rectum, whereas HT29 originated from the colon
[54,55].
Data from the Encyclopedia of DNA elements project
showed that the analyzed CpG rich region upstream of
HSD17B1 (chr17: 37 953 426-37 954 646) is able to
bind various transcription factors. Moreover, the
CN 
5-dAzaC
CN 
5-dAzaC
HT29
SW707
A 
B
Figure 5 Bisulfite sequencing of the CpG rich region fragment (A) and binding of Pol II to HSD17B1 promoter (B) in HT29 and SW707
colorectal cancer cells treated with 5-dAzaC. HT29 and SW707 cells were incubated for 48 h either in the absence or in the presence of 5-
dAzaC (1.00 μM). The cells were then used for genomic DNA isolation followed by bisulfite conversion of cytosine to uracil. The CpG rich region
containing 31 CpG dinucleotides (chr17: 37 953 392-37 953 917) was then amplified by a pair of primers complementary to the bisulfite-DNA
modified sequence (Additional file 1, Additional file 2). The PCR products were purified with subsequent cloning into a plasmid vector. Plasmid
DNA isolated from ten positive bacterial clones was used for commercial sequencing. The results of bisulfite sequencing were assessed and
presented using BiQ analyzer software and BDPC web server, respectively [22,23]. Black and grey boxes represent methylated and unmethylated
CpG dinucleotide, respectively. White boxes correspond to undetermined CpG dinucleotide. For the ChIP assay, HT29 and SW707 cells were
incubated for 0, 6, 12, 24, 36, and 48 h either in the absence or in the presence of 5-dAzaC (1.00 μM). After incubation, cells were used for ChIP
analysis with anti-Pol II Ab. RQ-PCR was carried out by pairs of primers complementary to the HSD17B1 promoter for the HT29 (-◆-) and SW707
(...▲...) cell lines (Additional file 1, Additional file 2). Data are expressed as a percentage of the HSD17B1 promoter occupied by Pol II. The results
are presented as the mean ± SE from three independent experiments.
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Page 10 of 13enrichment of histone modification and DNAse I hyper-
sensitivity of that region suggest promoter or enhancer
activity [56]. Lornicz et al. (2004) showed that DNA
methylation in intragenic and intergenic CpG rich
regions may convert euchromatin to heterochromatin
and lead to reduced Pol II action [57]. Based on this
observation, we hypothesize that hypermethylation of
the 5’ flanking region of the HSD17B1 gene might inhi-
bit the binding of transcription factors and decrease
HSD17B1 expression in CRC.
5-dAzaC has been considered in the treatment of
CRC. Genome-wide studies, including promoter methy-
lation and expression microarray analysis, revealed a
number of genes that are up-regulated in SW116 and
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Figure 6 Effect of 5-dAzaC in conversion of E1 to E2 in HT29 (A) and SW707 (B) colorectal cancer cells. Cells were cultured in phenol
red-free DMEM for 36 h either in the absence or in the presence of 5-dAzaC at a concentration of 1.00 μM for HT29 and SW707 cells. These
cells were then further cultured either in the absence or the presence of E1 at a concentration of 10
-2 mM. After 2, 4, 6, 8, 10 and 12 h, 0.5 ml of
the medium was collected and the concentration of E2 was determined by electrochemiluminescence method. The results were expressed as E2
concentration in culture medium as nM per μg cell proteins. Each sample was determined in triplicate and results are presented as the mean ±
SE from three experiments. The slope values were calculated according to nonlinear regression data fit from the log of Y axis values.
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Page 11 of 13Colo-320 CRC cells treated with 5-dAzaC [58]. This
DNMTs inhibitor also results in DNA demethylation
and induces the expression of PDZ and LIM domain 2,
UDP-glucuronosyltransferase 1A1, insulin-like growth
factor binding protein 7,a n dNGX6 genes in CRC cells
[47,48,59,60]. Lin et al. (2008) demonstrated that 5-
dAzaC induced apoptosis and inhibited the growth,
migration and invasion of colon cancer cells [60].
Conclusion
Our results showed increased DNA methylation in the
5’ flanking region of HSD17B1 in CRC from the proxi-
mal colon as compared to normal colonic epithelium.
These epigenetic differences were associated with a sig-
nificant reduction of HSD17B1 transcript and protein
levels in cancer located in the proximal colon. We also
found that 5-dAzaC, an inhibitor of DNMTs, induced
the demethylation of the 5’ flanking region of HSD17B1,
leading to increased transcript and protein levels in
HT29 colon cancer cells, which contributed to the
increase in E2 formation.
Although we presented that HSD17B1 expression in
CRC can be epigenetically down-regulated, further stu-
dies are required to assess the concentration of endo-
g e n o u sE 2i nn o r m a lc o l o n i ct i s s u ea n dt h er o l eo f
endogenous E2 in the prevention of carcinogenesis.
Additional material
Additional file 1: Organization of the HSD17B1 gene (A), the
positions of CpG-rich regions and promoter.
Additional file 2: Primer sequences.
Additional file 3: DNA methylation assessment by HRM analysis.
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